PUBLICATION
Esculetin Alleviates Nonalcoholic Fatty Liver Disease on High-Cholesterol-Diet-Induced Larval Zebrafish and FFA-Induced BRL-3A Hepatocyte
- Authors
- Ma, J., Deng, Y., Yang, T., Li, M., Shang, J.
- ID
- ZDB-PUB-230122-23
- Date
- 2023
- Source
- International Journal of Molecular Sciences 24(2): (Journal)
- Registered Authors
- Li, Maoru, Ma, Ji, Shang, Jing
- Keywords
- antioxidant, esculetin, lipid-lowering, non-alcoholic fatty liver disease
- MeSH Terms
-
- Non-alcoholic Fatty Liver Disease*/metabolism
- Hypercholesterolemia*/metabolism
- Liver/metabolism
- Hepatocytes/metabolism
- Zebrafish
- Cholesterol/metabolism
- Animals
- Diet, High-Fat
- Larva
- PubMed
- 36675107 Full text @ Int. J. Mol. Sci.
Citation
Ma, J., Deng, Y., Yang, T., Li, M., Shang, J. (2023) Esculetin Alleviates Nonalcoholic Fatty Liver Disease on High-Cholesterol-Diet-Induced Larval Zebrafish and FFA-Induced BRL-3A Hepatocyte. International Journal of Molecular Sciences. 24(2):.
Abstract
Non-alcoholic fatty liver disease (NAFLD), defined in recent years as metabolic-associated fatty liver disease (MAFLD), is one of the most common liver diseases in the world, with no drugs on market. Esculetin (ESC) is an active compound discovered in a variety of natural products that modulates a wide range of metabolic diseases and is a potential drug for the treatment of NAFLD. In this study, we used an HCD-induced NAFLD larval zebrafish model in vivo and an FFA-induced BRL-3A hepatocyte model in vitro to evaluate the anti-NAFLD effect of ESC. Lipid lowering, anti-oxidation and anti-inflammation effects were revealed on ESC and related gene changes were observed. This study provides a reference for further study and development of ESC as a potential anti-NAFLD/MAFLD drug.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping